{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:08:10Z","timestamp":1747156090336,"version":"3.40.5"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.beha.2016.08.004","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T01:55:55Z","timestamp":1470966955000},"page":"2-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["B cell receptor inhibition as a target for CLL therapy"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8822-1814","authenticated-orcid":false,"given":"Deepa","family":"Jeyakumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.08.004_bib1","unstructured":"https:\/\/www.lls.org\/sites\/default\/files\/file_assets\/facts.pdf; http:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"10.1016\/j.beha.2016.08.004_bib2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib3","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1126\/science.1071546","article-title":"B\u00a0cell antigen receptor signaling: roles in cell development and disease","volume":"296","author":"Gauld","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.beha.2016.08.004_bib4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.molcel.2004.06.015","article-title":"Perspectives on the nature of BCR-mediated survival signals","volume":"14","author":"Smith","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.beha.2016.08.004_bib5","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/0008-5472.CAN-08-4252","article-title":"Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia","volume":"69","author":"Buchner","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2016.08.004_bib6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib7","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O'Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.08.004_bib9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.004_bib10","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib11","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/asheducation-2014.1.125","article-title":"BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma","volume":"2014","author":"Wiestner","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2016.08.004_bib13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cbpa.2010.06.168","article-title":"Targeted covalent drugs of the kinase family","volume":"14","author":"Singh","year":"2010","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.beha.2016.08.004_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.004_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.004_bib16","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.08.004_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.08.004_bib19","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02048813."},{"key":"10.1016\/j.beha.2016.08.004_bib20","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT01886872."},{"key":"10.1016\/j.beha.2016.08.004_bib21","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib22","first-page":"1044","article-title":"Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches","volume":"26","author":"Stephens","year":"2012","journal-title":"Oncol (Williston Park)"},{"key":"10.1016\/j.beha.2016.08.004_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V124.21.327.327","article-title":"Efficacy and Safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the Phase II Resonate-17 Trial","volume":"124","author":"O'Brien","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib24","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2016.08.004_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.V122.21.525.525","article-title":"Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed\/refractory CLL\/SLL: final results of phase 1b study","volume":"122","author":"Brown","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib26","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia","volume":"125","author":"Brown","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib27","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1200\/jco.2015.33.18_suppl.lba7005","article-title":"Ibrutinib combined with bendamustine and rituximab (BR) in previously treated CLL\/SLL: first results of randomized double-blind placebo controlled phase III study","volume":"33","author":"Chanan-Khan","year":"2015","journal-title":"J Clin Onc"},{"key":"10.1016\/j.beha.2016.08.004_bib28","unstructured":"de Lartigue J. BTK pathway activity explodes. Oncpathways.56\u201359."},{"key":"10.1016\/j.beha.2016.08.004_bib29","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib30","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.08.004_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib33","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/blood.V122.21.866.866","article-title":"Clonal evolution in patients with chronic lymphocytic leukemia (CLL) developing resistance to BTK inhibition","volume":"122","author":"Burger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib34","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1182\/blood-2014-02-554220","article-title":"Kinetics of chronic lymphocytic leukemia (CLL) cells in tissues and blood during therapy with the BTK inhibitor ibrutinib","volume":"123","author":"Wodarz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib35","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib36","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood.V124.21.3335.3335","article-title":"Clinical activity of Duvelisib (IPI-145), a phosphoinositide- 3-kinsase-\u2202\/\u03b3 inhibitor in patients previously treated with ibrutinib","volume":"123","author":"Porcu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib37","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","article-title":"Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia","volume":"125","author":"Hing","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib38","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02303392."},{"key":"10.1016\/j.beha.2016.08.004_bib39","first-page":"676","article-title":"A Phase I study of oral BTK inhibitor ONO-4059 in patients with relapsed\/refractory or high-risk chronic lymphocytic leukemia (CLL)","volume":"122","author":"Sales","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11899-013-0188-8","article-title":"Bruton's tyrosine kinase (BTK) inhibitors in clinical trials","volume":"9","author":"Burger","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.beha.2016.08.004_bib41","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood.V122.21.1630.1630","article-title":"Phase I study of single agent CC-292, a highly selective Bruton's tyrosine kinase (BTK) inhibitor in patients previously treated with ibrutinib","volume":"122","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib42","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-2596","article-title":"ACP-196: a novel covalent Bruton's tyrosine kinase (BTK) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia","volume":"75","author":"Covey","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.beha.2016.08.004_bib43","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02029443."},{"key":"10.1016\/j.beha.2016.08.004_bib44","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02337829."},{"key":"10.1016\/j.beha.2016.08.004_bib45","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477696."},{"key":"10.1016\/j.beha.2016.08.004_bib46","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02157324."},{"key":"10.1016\/j.beha.2016.08.004_bib47","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02296918."},{"key":"10.1016\/j.beha.2016.08.004_bib48","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib49","article-title":"BGB-311 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.beha.2016.08.004_bib50","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02343120."},{"key":"10.1016\/j.beha.2016.08.004_bib51","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.clinthera.2013.08.004","article-title":"Targeted therapy in chronic lymphocytic leukemia: past, present, and future","volume":"35","author":"Danilov","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.beha.2016.08.004_bib52","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib53","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.beha.2016.08.004_bib54","article-title":"Second interim analysis of a phase 3 study of idelalisib (Zydelig) plus Rituximab for relapsed chronic lymphocytic leukemia: efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors","volume":"124","author":"Sharman","year":"2014","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.beha.2016.08.004_bib55","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02135133."},{"key":"10.1016\/j.beha.2016.08.004_bib56","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01569295."},{"key":"10.1016\/j.beha.2016.08.004_bib57","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT010980888."},{"key":"10.1016\/j.beha.2016.08.004_bib58","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01659021."},{"key":"10.1016\/j.beha.2016.08.004_bib59","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01203930."},{"key":"10.1016\/j.beha.2016.08.004_bib60","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2014-07-587279","article-title":"IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells","volume":"124","author":"Dong","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib61","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1182\/blood.V124.21.3334.3334","article-title":"Duvelisib (IPI-145), a PI3K-\u2202\/\u03b3 inhibitor, is clinically active in patients with relapsed\/refractory Chronic lymphocytic leukemia","volume":"124","author":"O'Brien","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib62","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02004522."},{"key":"10.1016\/j.beha.2016.08.004_bib63","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02158091."},{"key":"10.1016\/j.beha.2016.08.004_bib64","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02292225."},{"key":"10.1016\/j.beha.2016.08.004_bib65","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01871675."},{"key":"10.1016\/j.beha.2016.08.004_bib66","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02049515."},{"key":"10.1016\/j.beha.2016.08.004_bib67","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.2513","article-title":"Activity of TGR-1202, a novel once-daily PI3k\u03b4 inhibitor in patients with relapsed and refractory hematologic malignancies","volume":"32","author":"Burris","year":"2014","journal-title":"J Clin Onc"},{"key":"10.1016\/j.beha.2016.08.004_bib68","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1182\/blood.V124.21.1984.1984","article-title":"TGR-1202, a novel once daily PI3k\u03b4 inhibitor, demonstrates clinical activity with a favorable safety profile, lacking hepatotoxicity, in patients with chronic lymphocytic leukemia and B cell lymphoma","volume":"124","author":"Burris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib69","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8548","article-title":"Ublituximab plus TGR-1202 activity and safety profile in relapsed\/refractory B-cell NHL and high risk CLL","volume":"33","author":"Lunning","year":"2015","journal-title":"J Clin Onc"},{"key":"10.1016\/j.beha.2016.08.004_bib70","article-title":"Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202 and ibrutinib in relapsed B cell malignancies","volume":"33","author":"Folwer","year":"2015","journal-title":"J Clin Onc"},{"key":"10.1016\/j.beha.2016.08.004_bib71","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02268851."},{"key":"10.1016\/j.beha.2016.08.004_bib72","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02100852."},{"key":"10.1016\/j.beha.2016.08.004_bib73","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.V122.21.678.678","article-title":"First in human study of AMG-319, a highly selective, small molecule inhibitor of PI3k\u03b4, in adult patients with relapsed or refractory lymphoid malignancies","volume":"122","author":"Lanasa","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.004_bib74","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T03:32:10Z","timestamp":1601004730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1521692616300068"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B cell receptor inhibition as a target for CLL therapy","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}